Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans

Neuropsychopharmacology

Volumn 16, Issue 1, 1997, Pages 15-24

  Vitiello, Benedetto ^a   Martin, Alex ^a   Hill, James ^a   Mack, Carol ^a   Molchan, Susan ^a   Martinez, Rick ^a   Murphy, Dennis L ^a   Sunderland, Trey ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Cognition; Haloperidol; Metergoline; Scopolamine

Indexed keywords

HALOPERIDOL; METERGOLINE; PLACEBO; SCOPOLAMINE;

ADULT; ARTICLE; BEHAVIOR; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LEARNING; MALE; MEMORY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SEDATION; SEROTONINERGIC SYSTEM;

EID: 0031036526     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(96)00134-0     Document Type: Article

References (54)

1. Altman HJ, Normile HJ (1986): Enhancement of the memory of a previously learned aversive habit following pre-test administration of a variety of serotonergic antagonists in mice. Psychopharmacology 90:24-27
2. Beatty WW, Butters N, Janowsky DS (1986): Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neural Biol 45:196-211
3. Benton AL, Hamsher K, Varney NR, Spreen O (1983): Contributions to neuropsychological assessment. New York, Oxford University Press
4. Beretta C, Ferrini R, Glasser AH (1965): 1-methyl-beta-carbobenzyloxyaminomethyl-10-a-ergoline, a potent and long lasting 5-hydroxytryptamine antagonist. Nature 205:421-422
5. Berger HJC, Hoof JJK, van Spaendonck KPM, Horstink MWI, van den Bercken JHL, Jaspers R, Cools AR (1989): Haloperidol and cognitive shifting. Neuropsychologia 27:629-639
6. Bond AJ, Lader MH (1974): The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211-218
7. Bowen DM, Alien SJ, Benton JS, Goodhardt EA, Haan AM, Palmer NR, Sims NR, Smith CCT, Spillane JA, Esiri MM, Neary D, Snowdeon JS, Wilcock GK, Davison AN (1983): Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 41:266-272
8. Bubser M, Schmidt WJ (1990): 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition tasks, but does not affect uninterrupted tasks in the radial maze. Behav Brain Res 37:157-168
9. Caine ED, Weingartner H, Ludlow DL, Cudahy EA, Wehry S (1981): Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology 74:74-80
10. Chugh Y, Saha N, Sankaranarayanan A, Sharma PL (1991): Possible mechanism of haloperidol-induced enhancement of memory retrieval. Meth Find Exp Clin Pharmacol 13:161-164
11. Curcio CA, Kemper T (1984): Nucleus raphe dorsalis in dementia of the Alzheimer type: Neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 43:359-368
12. Drachman DA, Leavitt J (1974): Human memory and the cholinergic system. Arch Neurol 30:113-121
13. Dunne MP (1990): Scopolamine and sustained retrieval from semantic memory. J Psychopharmacol 4:13-18
14. Dunne MP, Statham D, Raphael B, Kemp R, Kelly B (1993): Further evidence that scopolamine can improve verbal fluency. J Psychopharmacol 7:159-163
15. Fleiss JL (1986): The design and analysis of clinical experiments. New York, Wiley
16. Flicker C, Ferris SH, Serby M (1992): Hypersensitivity to scopolamine in the elderly. Psychopharmacology 107:437-441
17. Flicker C, Serby M, Ferris SH (1990): Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100:243-250
18. Flood JF, Cherkin A (1987): Fluoxetine enhances memory processing in mice. Psychopharmacology 93:36-43
19. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993): The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48
20. Gottfries CG, Ross BE (1973): Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer's disease). Acta Psychiatr Scand 49:257-263
21. Hoyer D (1989): 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In Fozard JR (ed), The Peripheral Actions of 5-Hydroxytryptamine, Oxford, Oxford University Press, pp 72-99
22. Ketchum JS, Sidell FR, Crowell EB, Aghajanian GK, Hayes AH (1973): Atropine, scopolamine and ditran: Comparative pharmacology and antagonists in man. Psychopharmacologia (Berl) 28:121-145
23. King DJ (1990): The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 157:799-811
24. Kopelman MD, Corn TH (1988): Cholinergic "blockade" as a model for cholinergic depletion. Brain 111:1079-1110
25. Lezak MD (1983): Neuropsychological Assessment. New York, Oxford University Press
26. Littell RC, Freund RF, Spector PC (1991): SAS System for Linear Models. Cary, NC, SAS Institute Inc.
27. Little JT, Broocks A, Martin A, Hill JL, Mack C, Cantillon M, Molchan S, Murphy DL, Sunderland T (1995): Serotonergic modulation of anticholinergic effects in cognition and behavior in elderly humans. Psychopharmacology 120:280-288
28. Magliozzi JR, Mungas D, Laubly JN, Blunden D (1989): Effect of haloperidol on a symbol digit substitution task in normal adult males. Neuropsychopharmacology 2:29-37
29. Martin A, Fedio P (1983): Word production and comprehension in Alzheimer's disease: The breakdown of semantic knowledge. Brain Lang 19:124-141
30. Martin A, Pigott TA, LaLonde FM, Dalton I, Dubbert B, Murphy DL (1993): Lack of evidence for Huntington's disease-like cognitive dysfunction in obsessive-compulsive disorder. Biol Psychiatry 33:345-353
31. Martin PR, Adinoff B, Eckardt MJ, Stapleton JM, Bone G, Rubinow DR, Lane EA, Linnoila M (1989): Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Arch Gen Psychiatry 46:617-621
32. Martini A, Moro E, Marrari P, Pacciarini MA, Sega R, Dell'Osso L, Bertelli AJ, Tamassia V (1983): Pharmacokinetics and bioavailability of metergoline in healthy volunteers after single i.v. and oral administration. Int J Clin Pharmacol Res 3:27-34
33. 2dopaminergic antagonist drugs. Psychopharmacology 99:371-373
34. McGurk SR, Levin ED, Butcher LL (1989): Cholinergic-dopaminergic reactions in radial-arm maze performance. Behav Neural Biol 49:234-239
35. 2antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers. Br J Pharmacol 33:281-288
36. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T (1992): Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 17:215-226
37. Morgan DG, May PC, Finch CE (1987): Dopamine and serotonin systems in human and rodent brain: Effects of age and neurogenerative disease. J Am Geriatr Soc 35:334-345
38. Mungas D, Magliozzi JR, Laubly JN, Blunen D (1990): Effects of haloperidol on recall and information in verbal and spatial learning. Prog Neuropsychopharmacol Biol Psychiatr 14:181-193
39. Newcombe F (1969): Missile Wounds of the Brain. London, Oxford University Press
40. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 106:433-438
41. Overall JE, Gorham DR (1962): The brief psychiatric rating scale. Psychol Rep 10:799-812
42. Palmer AM, Francis PT, Benton JS, Sims NR, Mann DMA, Neary D, Snowden JS, Bowen DM (1987): Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 48:8-15
43. Peterson LR, Peterson MR (1959): Short-term retention of individual verbal items. J Exp Psychol 58:193-198
44. Petkov VD, Markovska VL, Petkov VV (1991): Effects of serotoninergic receptor antagonists and their combination with scopolamine on memory. Acta Physiol Pharmacol Bulg 17:21-28
45. Snodgrass JD, Corwin J (1988): Perceptual identification thresholds for 150 fragmented pictures from the Snodgrass and Vanderwart picture set. Percept Motor Skills 67:3-36
46. Sullivan EV, Corkin S, Growdon JH (1986): Verbal and non-verbal short-term memory in patients with Alzheimer's disease and in healthy elderly subjects. Dev Neuropsychol 2:387-400
47. Sunderland T, Tariot PN, Weingarten H, Murphy DL, Newhouse PA, Mueller EA, Cohen RM (1986): Pharmacologie modelling of Alzheimer's disease. Prog NeuroPsychopharmacol Biol Psychiatr 10:599-610
48. Sunderland T, Tariot PN, Cohen RM, Weingarten H, Mueller EA, Murphy DL (1987): Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: A dose-response study. Arch Gen Psychiatr 44:418-426
49. Van Kammen DP, Murphy DL (1975): Attenuation of the euphoriant and activating effects of d-and 1-amphetamine by lithium carbonate treatment. Psychopharmacologia 44:215-224
50. Vanderwolf CH (1987): Near-total loss of "learning" and "memory" as a result of combined cholinergic and serotonergic blockade in the rat. Behav Brain Res 23:43-57
51. Vanderwolf CH, Baker GB (1986): Evidence that serotonin mediates non-cholinergic neocortical low voltage fast activity, non-cholinergic hippocampal rhythmical slow activity and contributes to intelligent behavior. Brain Res 374:342-356
52. Warburton DM, Wesnes K (1985): Historical overview of research on cholinergic systems and behavior. Singh MM, Warburton MD, Lal H (eds), Central Cholinergic Mechanisms and Adoptive Dysfunctions, New York, Plenum, pp 1-36
53. Wechsler D (1955): Manual for the Wechsler Adult Intelligence Scale. New York, Psychological Corporation
54. Weingartner H, Grafman J, Boutelle W, Kaye W, Martin PR (1983): Forms of memory failure. Science 221:380-382